Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
The GLP-1 receptor agonist market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 to 2032 for the following segments: By Drug Class Semaglutide Dulaglutide Liraglutide Exenatide Other drug classes By Route of Administration Parenteral Oral By Application Type 2 diabetes mellitus Obesity Other applications By Distribution Channel Hospital pharmacies Retail pharmacies Online pharmacies The above information is provided for the following regions and countries: North America U.S
Wegovy comes in a 2.4 mg fixed-dose pen at the maintenance dose, which means each pen lasts roughly 4 injections (one per week) for the top dose
A) all generic cos were very low on their GLP1 forecast before the launch - a few 10s of crores at best in the 1st year eg A top co in India had a 10cr first yr sales forecast and is set to do a multiplier of that On top of that fewer than expected cos have launched B) online sales which is the biggest area of growth on GLP1s (pharmacies / Telehealth) doesnt get captured and so is direct sales
Additionally, nanocarriers can be used to improve the stability and delivery of peptide drugs when sonication is applied
US$ 23.93
US$ 26.89
US$ 29.24
US$ 29.38
